(NASDAQ: LPCN) Lipocine's forecast annual revenue growth rate of 7.22% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 3,065.21%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 55.62%.
Lipocine's revenue in 2025 is $3,674,835.On average, 1 Wall Street analysts forecast LPCN's revenue for 2025 to be $21,080,403, with the lowest LPCN revenue forecast at $21,080,403, and the highest LPCN revenue forecast at $21,080,403.
In 2026, LPCN is forecast to generate $21,401,424 in revenue, with the lowest revenue forecast at $21,401,424 and the highest revenue forecast at $21,401,424.